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AbstrAct
Next generation sequencing has shown the frequent occurrence of point 
mutations in the ubiquitin E3 ligase c-Cbl in myeloid malignancies. Mouse models 
revealed a causal contribution of c-Cbl for the onset of such neoplasms. The point 
mutations typically cluster in the linker region and RING finger domain and affect both 
alleles by acquired uniparental disomy. The fast progress in the detection of c-Cbl 
mutations is contrasted by our scarce knowledge on their functional consequences. 
The c-Cbl protein displays several enzymatic functions by promoting the attachment 
of differentially composed ubiquitin chains and of the ubiquitin-like protein NEDD8 to 
its target proteins. In addition, c-Cbl functions as an adapter protein and undergoes 
phosphorylation-dependent inducible conformation changes. Studies on the impact 
of c-Cbl mutations on its functions as a dynamic and versatile adapter protein, its 
interactomes and on its various enzymatic activities are now important to allow the 
identification of druggable targets within the c-Cbl signaling network.
IntroductIon
Myeloid malignancies comprise three broad 
categories: acute myelogenous leukemia (AML) 
characterized by accumulation of immature myeloid cells 
in the bone marrow, myelodypastic syndromes (MDS) 
associated with ineffective hematopoiesis and chronic 
myeloproliferative disorders (MPDs), usually associated 
with an increased production of terminally differentiated 
myeloid cells. Despite this heterogeneity, all myeloid 
malignancies originate from progenitors that normally 
give rise to terminally differentiated cells of the myeloid 
series. Genetic and epigenetic events occurring early in 
hematopoietic stem cell maturation can lead to myeloid 
malignancies. Mutations can disrupt the normal course 
of hematopoiesis, resulting in a wide range of defects 
affecting the myeloid lineages [1].
Normal hematopoiesis involves a strict hierarchy 
of hematopoietic progenitor cells. The single primary 
source for the entire mammalian blood system is the 
hematopoietic stem cell (HSC), which is both multipotent 
and self-renewing in the absence of differentiation [2]. 
HSCs initially give rise to multipotent progenitors (MPPs), 
which have lost the ability to self-renew, but still maintain 
full-lineage differentiation potential [3]. MPPs can 
differentiate into common myeloid progenitors (CMPs), 
leading eventually to the generation of the myeloid lineage 
[2, 4-8]. 
Some myeloid malignancies are characterized by 
prominent and characteristic disease-causing mutations. 
For example, the vast majority of Polycythemia vera 
patients carry gain-of function mutations in Janus 
kinase 2 (JAK2 V617F) [9], while a hallmark of chronic 
myeloid leukemia (CML) is the generation of BCR-
ABL fusion proteins [10]. On the other hand, two thirds 
of patients with myelodysplastic/myeloproliferative 
neoplasms (MDS/MPN) have a normal karyotype, but 
have several oncogenic mutations in a variety of genes 
encoding proteins involved in RNA splicing, chromatin 
modification, transcription or signaling [11]. A substantial 
fraction of MDS/MPN and their subtypes is characterized 
by the frequent occurrence of mutations in the gene 
encoding c-Cbl (Casitas B-lineage Lymphoma), a protein 
whose various enzymatic and non-enzymatic functions are 
now beginning to emerge. 
Oncotarget10690www.impactjournals.com/oncotarget
Architecture and function of c-cbl proteins
The attachment of ubiquitin to its client proteins 
regulates many different biological processes and occurs 
by a complex enzymatic cascade [12]. This process is 
critically dependent on ubiquitin activation by the E1 
enzymes, followed by transfer of the activated ubiquitin 
to an ubiquitin-conjugating enzyme (E2) and finally, 
conjugation of ubiquitin to the target protein by an 
ubiquitin-protein ligase (E3). The E3 family of ubiquitin-
protein ligases has a crucial role in substrate recognition 
and is of great importance in the (patho)physiology of 
intracellular signaling networks [13, 14]. Among E3 
ligases, the small family of Cbl ubiquitin E3 ligases 
consists of the ubiquitously expressed proteins c-Cbl and 
Cbl-b as well as Cbl-c, which occur primarily in epithelial 
cells. All Cbl proteins share an N-terminal tyrosine-kinase-
binding (TKB) domain that is followed by a RING (really 
interesting new gene) finger and a proline-rich domain 
[15]. The TKB domain is a modified SH2 (Src homology 
2) domain that allows binding to phosphorylated tyrosines 
typically found in Cbl-interacting proteins. Cbl proteins 
are activated by phosphorylation at Y371 located in a 
linker region between the RING finger and the TKB 
domain [16]. This phosphorylation releases Cbl from its 
autoinhibited structure by triggering a conformational 
change that results in increased binding of the ubiquitin 
conjugating protein (or E2) to the RING finger of Cbl. 
This in turn leads to an enhanced transfer of ubiquitin 
from the E2 enzyme to the substrate proteins [17, 18]. The 
C-termini of Cbl-b and c-Cbl harbor extended proline-rich 
sequences and also a domain involved in ubiquitin binding 
and dimerization [19]. These domains allow for regulated 
protein/protein interactions via inducible association 
with SH2 and SH3 (Src homology 3) domain-containing 
proteins, as schematically displayed in Figure 1. 
Cbl proteins can exert multiple enzymatic functions. 
They can attach K48-branched polyubiquitin chains, 
resulting in proteasomal degradation of the decorated 
client proteins [20]. Cbl E3 ligases can also mediate the 
attachment of either K63-conjugated ubiquitin chains or 
single ubiquitin molecules to their substrate proteins to 
mediate non-proteolytic regulatory functions [21]. Recent 
evidence shows that c-Cbl also has the ability to mediate 
attachment of the ubiquitin-like protein NEDD8 (neural 
precursor cell expressed, developmentally down-regulated 
8) to substrate proteins. It was shown that c-Cbl-mediated 
neddylation of the TGF-β type II receptor antagonizes 
its ubiquitination and degradation [22]. Currently, it 
is not clear what molecular events guide Cbl proteins 
to distinguish between these four distinct enzymatic 
functions. 
In addition to these enzymatic activities, the various 
domains in Cbl proteins enable its function as an adapter 
by allowing constitutive or phososphorylation-dependent 
association with a plethora of different proteins [15, 
23]. The dual function of c-Cbl as an enzyme and as an 
adapter protein is schematically displayed in Figure 2. 
Given the multiplicity of interaction partners and its 
various enzymatic functions it is not surprising that Cbl 
proteins affect signaling pathways involved in a wide 
range of processes, including the immune response, 
endocytic sorting, apoptosis and autophagy [24-26]. 
Single nucleotide polymorphism screens and sequencing 
showed that myeloproliferative neoplasms frequently 
show mutations in c-Cbl, but not in the other members 
of the Cbl family [27-29]. While mutations of c-Cbl are 
frequently discovered in myeloid neoplasms, mutations of 
the other Cbl family members, Cbl-b and Cbl-c, are hardly 
detected [30]. So far only five mutations within the RING 
finger domain of Cbl-b were reported, which likely disrupt 
its function as a ubiquitin E3 ligase [31, 32].
c-cbl mutations in myelodysplastic and 
myeloproliferative neoplasms
Although approximately 10% of myeloid neoplasms 
show c-Cbl mutations, their frequency varies considerably 
between the subtypes. For example, while de novo AML 
has a relatively low frequency of such mutations at around 
1-3%, juvenile myelomonocytic leukemia (JMML) 
and chronic myelomonocytic leukaemia (CMML) have 
the highest frequencies of c-Cbl mutations of around 
13-15% [33-35]. Mutations in c-Cbl are typically 
nucleotide substitutions or small insertions/deletions 
that are heavily enriched in exons 8 and 9 and occur in 
the linker or RING finger domain of c-Cbl [27, 28, 36, 
37]. Approximately 85% of the mutations are point 
mutations and approximately 15% are small deletions of 
the linker and RING finger regions. Approximately 10% 
of patients with MDS/MPN show c-Cbl mutations and 
frequently display clinical features such as splenomegaly, 
monocytosis and anemia [38]. Of the point mutations, 
about 70% are homozygous due to acquired uniparental 
disomy (aUPD), where both copies of a chromosome 
pair or parts of chromosomes have originated from one 
parent. Thus aUPD is a mechanism by which pathogenetic 
mutations in cancer may be reduced to homozygosity. 
Thus, an allelic conversion of the 11q arms leads to 
duplication of the mutated parental copy of 11q and loss 
of the remaining wild-type allele, resulting in homozygous 
c-Cbl mutations [36]. These mutations frequently result 
in the loss of ubiquitin E3 ligase activity [36], thus 
prohibiting lysosomal or ubiquitin/proteasome-mediated 
degradation of tyrosine kinases and thereby unleashing 
tyrosine kinase signaling. Therefore, although these 
mutations cause biochemical loss-of-function of c-Cbl, 
their functional consequences resemble classical gain-of-
function mutations.
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Figure 2: schematic summary of c-cbl functions as an adapter protein and as an enzyme. Inducible interactions by 
the ubiquitin binding domain and phosphotyrosine/SH2 interactions are shown. The various enzymatic functions mediating different 
modifications of the substrate proteins (grey) are displayed. 
Figure 1: schematic display of the c-cbl structure. The various domains are given in colors, 4H: four helical bundle, EF: EF-hand 
calcium-binding domain, SH2: Src homology 2, L: linker helical region, P: proline-rich, U: Ubiquitin-binding domain. The phosphorylated 
tyrosines in the C-terminus allow docking of the indicated proteins and the frequently mutated region is highlighted. 
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Mechanisms of c-cbl mediated oncogenic 
transformation 
The causal contribution of c-Cbl to the onset of 
myeloid malignancies was revealed in mouse models. 
c-Cbl-deficient mice are viable but show lymphoid 
hyperplasia, enhanced T-cell signaling and primary 
splenic extramedullary hemopoiesis [39]. In contrast, 
mice lacking Cbl-b do not share phenotypes with c-Cbl-
null mice and are characterized by a reduced T-cell 
activation threshold. Mice with combined deletion of 
c-Cbl and Cbl-b in hematopoietic stem cells develop an 
early-onset lethal myeloproliferative disease within the 
first months after birth [40]. Mice engineered to express 
a c-Cbl RING domain point mutation (C379A) develop 
a myeloproliferative disease that progresses to leukemia 
[41], thus classifying c-Cbl mutations as driver mutations. 
This phenotype is even more severe than that of c-Cbl-
deficient mice, suggesting that c-Cbl mutations act in 
a dominant negative manner and also affect the other 
endogenous members of the Cbl family. In addition 
to its function as a dominant negative protein mutant 
c-Cbl may also act as a positive signaling protein via its 
adaptor function. While a single c-Cbl point mutation 
can cause myeloid malignancies in mice, the situation is 
markedly different in humans. This difference is unlikely 
to be attributable to differences in expression levels or 
other experimental settings, as in humans over 10% 
of the tumors carry c-Cbl mutations together with 2-4 
additional characteristic mutations [11, 37]. Furthermore, 
mutations at amino-acid residue C381 in human c-Cbl 
(equivalent to amino-acid residue C379 in mouse c-Cbl) 
amounts to ~0.8% of the mutations identified. The relative 
contribution of c-Cbl to development of MDS/MPN might 
be underestimated because some other genes known to be 
mutated or amplified in MDS/MPN, such as the duplicated 
gene encoding the SH3KBP1 (SH3-domain kinase binding 
protein) adapter protein, are part of the c-Cbl-regulated 
signaling network and may have the same effect as a c-Cbl 
mutation [42]. In addition, inactivation of c-Cbl may be 
mediated by events that do not affect the c-Cbl sequence. 
Phosphatases may keep c-Cbl in an inactivated state 
and increased auto-ubiquitination can limit the available 
protein amounts of the E3 ligase in tumor cells. Novel 
proteogenomic approaches for characterization of tumor 
cells will enable completely new insights in the relative 
protein abundance of c-Cbl and its client proteins [43]. In 
humans, c-Cbl mutations are not typical founding driver 
mutations allowing the first step in the leukemogenic 
process, but rather occur as subclonal secondary driver 
mutations, ensuring the further progress of the disease. 
Support for this model comes from the analysis of a 
patient with essential thrombocythemia, who had an intact 
c-Cbl gene at the early stage of disease, but acquired a 
c-Cbl R420Q mutation during disease progression to 
myelofibrosis [29]. The concept of c-Cbl mutations as 
secondary driver mutations is recapitulated in an animal 
model where transgenic mice expressing the oncogenic 
fusion protein NHD13 (NUP98-HOXD13) develop a 
myelodysplastic syndrome, which proceeds to acute 
leukemia. These animals pick up several secondary driver 
mutations in several genes including c-Cbl [44]. A deep 
sequencing study performed with a cell colony derived 
from a single cell detected ten mutations, compatible with 
the concept of a linear evolution of a dominant clone [34]. 
Recent advances in single cell genomics will now enable 
a detailed view into the stepwise acquisition of primary 
and secondary driver mutations [45]. It was suggested that 
c-Cbl mutations might indicate a poor clinical prognosis 
[38], but this is not consistently seen in other studies 
[46, 47]. It will be therefore important to consider also 
the prognostic value of these co-occurring secondary 
mutations in the future. 
The importance of c-Cbl to myeloid differentiation 
and cancer is likely due to its involvement in numerous 
signaling pathways and biological functions. Mutation of 
c-Cbl can lead to aberrant activation of the JAK-STAT 
and PI3K-AKT pathways to transmit mitogenic and/or 
survival signals [48-50]. The mutant c-Cbl protein can 
also affect cytoskeleton organization via activation of 
Rac1 or Cdc42, and R-RAS [51] and affects integrin-
mediated cell adhesion, spreading, and migration [52, 
53]. Cbl proteins are important for the control of signaling 
thresholds in immune cells, and point mutations of c-Cbl 
consistently lead to enhanced granulocyte-macrophage 
colony-stimulating factor (GM-CSF)-triggered signaling 
via STAT5 and JAK2 [54, 55]. 
Cbl also contributes to myeloid differentiation by 
regulating the activity of colony stimulating factor-1 
(CSF-1) receptor (CSF-1R). In the hematopoietic 
system, CSF-1 is believed to act specifically on myeloid 
progenitors, starting from the CMP stage, and to favour the 
differentiation of CMPs into the monocyte/macrophage 
lineage [56]. Indeed, transgenic mice engineered to 
secrete human CSF-1 show augmented frequencies and 
functions of human myeloid cells [57]. CSF-1 can directly 
induce the myeloid master regulator PU.1 and thus instruct 
myeloid cell-fate change in mouse HSCs both in vitro and 
in vivo [58]. Furthermore, intra-hepatic transfer of human 
fetal liver derived hematopoietic stem and progenitor cells 
(CD34+) in humanized CSF-1 newborn mice resulted in 
more efficient differentiation and enhanced frequencies 
of human monocytes/macrophages in the bone marrow, 
spleens, peripheral blood, lungs, liver and peritoneal 
cavity, pointing to its potential role in myeloid cell fate 
[57]. The magnitude and duration of signaling through 
activated CSF-1R is tightly regulated by its c-Cbl mediated 
ubiquitination-dependent down-regulation [59-61]. These 
c-Cbl-mediated effects on soluble factors such as CSF-1 
raise the intriguing possibility that an oncogenic mutation 
in one tumor cell might affect neighbouring wildtype cells 
by paracrine mechanisms. 
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Future directions
Accumulating clinical evidence shows that 
progression mutations in c-Cbl and other key regulators 
occur during further clonal development of myeloid 
malignancies. Unlike the classical gain-of-function 
mutations exemplified by constitutive active JAK2 
(V617F) or BCR-ABL [62], mutant c-Cbl has lost its 
enzymatic activity which renders it not an obvious 
drug target. This raises the need to identify druggable 
downstream components of the c-Cbl signaling pathways. 
Therefore, the downstream effectors of c-Cbl such as the 
JAK/STAT, PI3K, and ERK signaling pathways have been 
suggested as potential therapeutic targets. However, drugs 
acting on these signaling endpoints will not be specific 
for myeloid malignancies. As mutant c-Cbl proteins 
could display residual enzymatic activities as E3 ligases it 
may also be feasible to inhibit deubiquitinating enzymes 
that counteract c-Cbl. In order to develop drugs that are 
specifically tailored for the treatment of myeloid tumors 
with c-Cbl mutations we need a better understanding 
of the functional consequences of these mutations. 
The importance of this concept has been demonstrated 
by the use of mice with a c-Cbl RING finger mutation 
that develop a myeloproliferative disease progressing 
to leukemia. These mice exhibit augmented FLT3 (fms-
related tyrosine kinase 3) signaling and inhibition of 
FLT3 kinase activity by quizartinib (AC220) effectively 
suppresses MPD development [41]. Deciphering how 
individual c-Cbl mutations affect its different enzymatic 
functions (neddylation, monoubiquitination, regulatory or 
proteolytic polyubiquitination) will provide therapeutic 
clues. As the activity of c-Cbl proteins is regulated by 
conformational changes [17, 18], it will be important 
to determine changes in the interactomes between 
wildtype and oncogenically mutated proteins. Also 
the intracellular localization of mutant c-Cbl and its 
posttranslational modifications need to be investigated, 
as phosphorylation of Y700 enables the interaction 
with further signal transmitting enzymes such as Vav1 
[63], while phosphorylation at Y731 and Y774 allows 
binding of the p85 subunit of PI3K and the Crk-family 
of adapter proteins, respectively [48, 64]. Along this 
line, a comparative analysis of phosphoproteomes in 
cells expressing wildtype or mutant c-Cbl would help 
in the exploration of deregulated signaling pathways. 
New genetic tools such as inducibly expressed shRNAs 
or CRISPR-Cas9-mediated genome editing will 
enable synthetic lethality screens to identify druggable 
interactions between mutant c-Cbl and further components 
of the signaling network. 
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AML: acute myelogenous leukemia; aUPD: 
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